Literature DB >> 19737610

Glucose and corticosterone changes in developing and adult rats following exposure to (+/-)-3,4-methylendioxymethamphetamine or 5-methoxydiisopropyltryptamine.

Devon L Graham1, Nicole R Herring, Tori L Schaefer, Charles V Vorhees, Michael T Williams.   

Abstract

The use of the club drugs 3,4-methylenedioxymethamphetamine (MDMA) and 5-methoxy-n,n-diisopropyltryptamine (Foxy) is of growing concern, especially as many of the effects, particularly during development, are unknown. The effects of these drugs upon homeostasis may be important since both are known to stimulate the hypothalamic-pituitary-adrenal axis. The purpose of this experiment was to examine alterations in rats in corticosterone and glucose following an acute exposure to these drugs at different stages of development: preweaning, juvenile, and adulthood. Both MDMA and Foxy increased corticosterone levels significantly at all ages examined, while glucose was elevated at all stages except at the juvenile time point (postnatal day 28). For both measures, there were no differences between the sexes with either drug. The data indicate that an acute exposure to these drugs alters CORT and glucose levels, raising the possibility that these changes may have effects on behavioral and cognitive function, as we and others have previously demonstrated. Copyright (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19737610      PMCID: PMC2839063          DOI: 10.1016/j.ntt.2009.08.012

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  71 in total

Review 1.  MDMA use and neurocognition: a meta-analytic review.

Authors:  Ari D Kalechstein; Richard De La Garza; James J Mahoney; William E Fantegrossi; Thomas F Newton
Journal:  Psychopharmacology (Berl)       Date:  2006-11-03       Impact factor: 4.530

2.  3,4-Methylenedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain.

Authors:  Altaf S Darvesh; Mahalakshmi Shankaran; Gary A Gudelsky
Journal:  J Pharmacol Exp Ther       Date:  2002-04       Impact factor: 4.030

3.  Activation of 5-HT2 receptors induces glycogenolysis in the rat brain.

Authors:  Altaf S Darvesh; Gary A Gudelsky
Journal:  Eur J Pharmacol       Date:  2003-03-19       Impact factor: 4.432

4.  Characteristics of pregnant women who use ecstasy (3, 4-methylenedioxymethamphetamine).

Authors:  E Ho; L Karimi-Tabesh; G Koren
Journal:  Neurotoxicol Teratol       Date:  2001 Nov-Dec       Impact factor: 3.763

5.  5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter.

Authors:  C Sogawa; N Sogawa; J Tagawa; A Fujino; K Ohyama; M Asanuma; M Funada; S Kitayama
Journal:  Toxicol Lett       Date:  2007-02-21       Impact factor: 4.372

6.  Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress.

Authors:  Michael T Williams; LaRonda L Morford; Sandra L Wood; Stephanie L Rock; Anne E McCrea; Masao Fukumura; Tanya L Wallace; Harry W Broening; Mary S Moran; Charles V Vorhees
Journal:  Brain Res       Date:  2003-04-04       Impact factor: 3.252

Review 7.  The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors:  A Richard Green; Annis O Mechan; J Martin Elliott; Esther O'Shea; M Isabel Colado
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

8.  Foxy, a designer tryptamine hallucinogen.

Authors:  Robert Meatherall; Pankaj Sharma
Journal:  J Anal Toxicol       Date:  2003 Jul-Aug       Impact factor: 3.367

9.  Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilisation in the Dark Agouti rat.

Authors:  Linda Quate; Douglas E McBean; Isobel M Ritchie; Henry J Olverman; Paul A T Kelly
Journal:  Psychopharmacology (Berl)       Date:  2004-02-20       Impact factor: 4.530

10.  Neuropsychological function in ecstasy users: a study controlling for polydrug use.

Authors:  Jonathan P Roiser; Robert D Rogers; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2005-09-15       Impact factor: 4.530

View more
  5 in total

1.  Effects of developmental stress and lead (Pb) on corticosterone after chronic and acute stress, brain monoamines, and blood Pb levels in rats.

Authors:  Devon L Graham; Curtis E Grace; Amanda A Braun; Tori L Schaefer; Matthew R Skelton; Peter H Tang; Charles V Vorhees; Michael T Williams
Journal:  Int J Dev Neurosci       Date:  2010-10-08       Impact factor: 2.457

2.  Electroencephalographic and convulsive effects of binge doses of (+)-methamphetamine, 5-methoxydiisopropyltryptamine, and (±)-3,4-methylenedioxymethamphetamine in rats.

Authors:  Devon L Graham; Nicole R Herring; Tori L Schaefer; Katherine D Holland; Charles V Vorhees; Michael T Williams
Journal:  Open Neuropsychopharmacol J       Date:  2012

3.  The effects of ecstasy on liver function tests, blood glucose, and lipids profile of male rats.

Authors:  Mohammad Reza Shahraki; Mahdieh Irani
Journal:  Int J High Risk Behav Addict       Date:  2014-09-17

4.  Sex-dependent psychoneuroendocrine effects of THC and MDMA in an animal model of adolescent drug consumption.

Authors:  Alvaro Llorente-Berzal; Emma Puighermanal; Aurelijus Burokas; Andrés Ozaita; Rafael Maldonado; Eva M Marco; Maria-Paz Viveros
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

Review 5.  Adolescent brain cognitive development (ABCD) study: Overview of substance use assessment methods.

Authors:  Krista M Lisdahl; Kenneth J Sher; Kevin P Conway; Raul Gonzalez; Sarah W Feldstein Ewing; Sara Jo Nixon; Susan Tapert; Hauke Bartsch; Rita Z Goldstein; Mary Heitzeg
Journal:  Dev Cogn Neurosci       Date:  2018-02-21       Impact factor: 5.811

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.